We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Strength Seen in Masimo (MASI): Can Its 7.7% Jump Turn into More Strength?
Read MoreHide Full Article
Masimo (MASI - Free Report) shares rallied 7.7% in the last trading session to close at $149.42. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 39.4% loss over the past four weeks.
Masimo recorded a strong price increase driven by its recently announced major expansion of its leading hospital remote patient monitoring and clinician notification platform — Masimo Patient SafetyNet. The expansion includes the addition of secure telehealth capabilities, thereby making the solution more adaptable and comprehensive. Per management, telehealth for Patient SafetyNet is expected to allow clinicians to collaborate and communicate in advanced but intuitive and efficient ways. This is likely to ultimately lead to improvements in patient outcomes and reduction of the cost of care.
This medical technology company is expected to post quarterly earnings of $1.02 per share in its upcoming report, which represents a year-over-year change of +13.3%. Revenues are expected to be $331.01 million, up 10.7% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Masimo, the consensus EPS estimate for the quarter has been revised 3.8% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on MASI going forward to see if this recent jump can turn into more strength down the road.
Masimo is part of the Zacks Medical - Instruments industry. Artivion (AORT - Free Report) , another stock in the same industry, closed the last trading session 4.5% higher at $20.39. AORT has returned 8.4% in the past month.
Artivion's consensus EPS estimate for the upcoming report has changed -157.8% over the past month to -$0.04. Compared to the company's year-ago EPS, this represents a change of +50%. Artivion currently boasts a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Strength Seen in Masimo (MASI): Can Its 7.7% Jump Turn into More Strength?
Masimo (MASI - Free Report) shares rallied 7.7% in the last trading session to close at $149.42. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 39.4% loss over the past four weeks.
Masimo recorded a strong price increase driven by its recently announced major expansion of its leading hospital remote patient monitoring and clinician notification platform — Masimo Patient SafetyNet. The expansion includes the addition of secure telehealth capabilities, thereby making the solution more adaptable and comprehensive. Per management, telehealth for Patient SafetyNet is expected to allow clinicians to collaborate and communicate in advanced but intuitive and efficient ways. This is likely to ultimately lead to improvements in patient outcomes and reduction of the cost of care.
This medical technology company is expected to post quarterly earnings of $1.02 per share in its upcoming report, which represents a year-over-year change of +13.3%. Revenues are expected to be $331.01 million, up 10.7% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Masimo, the consensus EPS estimate for the quarter has been revised 3.8% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on MASI going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Masimo is part of the Zacks Medical - Instruments industry. Artivion (AORT - Free Report) , another stock in the same industry, closed the last trading session 4.5% higher at $20.39. AORT has returned 8.4% in the past month.
Artivion's consensus EPS estimate for the upcoming report has changed -157.8% over the past month to -$0.04. Compared to the company's year-ago EPS, this represents a change of +50%. Artivion currently boasts a Zacks Rank of #3 (Hold).